Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
0 hedge funds and large institutions have $0 invested in Peak Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $314K → $0 (-$314K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$314K |
PKBO Hedge Fund Activity: Q2 2023 in Review
0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q2 2023, worth a combined $0 — down 100% from $314K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PKBO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Palo Alto Investors, exiting entirely with an estimated $314K sold.
- 0 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q2 2023, down from 1 in Q1 2023.
- Funds reported $0 of Peak Bio, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Peak Bio, Inc. Common Stock positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Peak Bio, Inc. Common Stock seller in Q2 2023 was Palo Alto Investors, an estimated $314K sold.
Based on aggregated 13F filings for Q2 2023.